semaglutide clinical trial weight loss as a GLP-1 Agonist: A Breakthrough in Obesity Treatment SELECT Trial

Published research suggests that the addition of glucagon receptor activity to the GLP-1/GIP agonist profile may produce metabolic effects not achievable through dual agonism alone

Appetite suppressants such as phentermine can be taken with semaglutide in addition to exercise and lifestyle changes, but they need strict medical supervision to prevent potential side effects

First-in-human phase 1 study of morab-202, an antibodydrug conjugate comprising farletuzumab linked to eribulin mesylate, in patients with folate receptor-positive advanced solid tumors

This can happen for several reasons

To view or add a comment, sign in Groundbreaking research from Duke University School of Medicine is changing our understanding of blood sugar regulation